Skip to main content
. 2022 Mar 17;29(3):2021–2045. doi: 10.3390/curroncol29030164

Table 2.

Proportion of patients on each of BSC treatments.

Treatment Proportion of Patients on Intervention in Base Case (%)
Rituximab 68.2%
Bendamustine 57.4%
Bortezomib 5.5%
Anthracycline-based 7.3%
Total 138.5%

Note: Sum is more than 100% as patients can be given these drugs in combination.